CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis

Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol consumption in C57BL/6J mice. In this report, a series of experiments were performed to further characterize the role of CRFR signaling in binge-like ethanol cons...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropsychopharmacology (New York, N.Y.) N.Y.), 2010-05, Vol.35 (6), p.1241-1252
Hauptverfasser: Lowery, Emily G, Spanos, Marina, Navarro, Montserrat, Lyons, Angela M, Hodge, Clyde W, Thiele, Todd E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1252
container_issue 6
container_start_page 1241
container_title Neuropsychopharmacology (New York, N.Y.)
container_volume 35
creator Lowery, Emily G
Spanos, Marina
Navarro, Montserrat
Lyons, Angela M
Hodge, Clyde W
Thiele, Todd E
description Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol consumption in C57BL/6J mice. In this report, a series of experiments were performed to further characterize the role of CRFR signaling in binge-like ethanol consumption. The role of central CRFR signaling was assessed with intracerebroventricular (i.c.v.) infusion of the nonselective CRFR antagonist, α -helical CRF 9–41 (0, 1, 5, 10 μg/1 μl). The contribution of central CRF type 2 receptor (CRF 2 R) signaling was assessed with i.c.v. infusion of the selective CRF 2 R agonist, urocortin (Ucn) 3 (0, 0.05, 0.1, or 0.5 μg/1 μl). The role of the hypothalamic–pituitary–adrenal (HPA) axis was assessed by pretreating mice with intraperitoneal (i.p.) injection of (1) the corticosterone synthesis inhibitor, metyrapone (0, 50, 100, 150 mg/kg) or (2) the glucocorticoid receptor antagonist, mifepristone (0, 25, 50 mg/kg), and (3) by using radioimmunoassay to determine whether binge-like ethanol intake influenced plasma corticosterone levels. Finally, we determined whether the ability of the CRF 1 R antagonist, CP-154,526 (CP; 0, 10, 15 mg/kg, i.p.), to blunt binge-like drinking required normal HPA axis signaling by comparing the effectiveness of CP in adrenalectomized (ADX) and normal mice. Results showed that i.c.v. infusion of a 1 μg dose of α -helical CRF 9–41 significantly attenuated binge-like ethanol consumption relative to vehicle treatment, and i.c.v. infusion of Ucn 3 dose-dependently blunted binge-like drinking. On the other hand, metyrapone nonselectively reduced both ethanol and sucrose consumption, mifepristone did not alter ethanol drinking, and binge-like drinking did not correlate with plasma corticosterone levels. Finally, i.p. injection of CP significantly attenuated binge-like ethanol intake in both ADX and normal mice. Together, these results suggest that binge-like ethanol intake in C57BL/6J mice is modulated by CRF 1 R and CRF 2 R signaling, such that blockade of CRF 1 R or activation of CRF 2 R effectively reduces excessive ethanol intake. Furthermore, normal HPA axis signaling is not necessary to achieve binge-like drinking behavior.
doi_str_mv 10.1038/npp.2009.209
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2927867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746011508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-9f3dc23d61390e81f07f51be69853dcee8104e9974a0627f0c8cf36b9ef6e4263</originalsourceid><addsrcrecordid>eNptkd1rFDEUxYModlt981mCIL44bT5mksmLMN22trKiiELfQjZ7s5t2NhmT2aL_vVl2bVV8uYFzfzk54SD0gpJjSnh7EobhmBGiylCP0ITKmlSC19eP0YS0ileU8-sDdJjzDSG0kaJ9ig4YoZw0nE_QOP1yUVHchdEsY_B5xCYs8FZkuNsrZ2ATmAz41IclVDN_C_h8XJkQe3yWfLgtMvYBTxt5OjsRH_BHbwFfhQUMUEYYcXR4XAG-_Nzh7ofPz9ATZ_oMz_fnEfp2cf51elnNPr2_mnazypacY6UcX1jGF4JyRaCljkjX0DkI1TZlA0UiNSgla0MEk47Y1jou5gqcgJoJfoTe7XyHzXwN5UYYk-n1kPzapJ86Gq__3gS_0st4p5lishWyGLzZG6T4fQN51GufLfS9CRA3WctaEEob0hby1T_kTdykUH6nGWsY4bKpC_R2B9kUc07g7qNQordl6lKm3pZZhir4yz_j38O_2yvA6z1gsjW9SyZYnx84JoVqxNao2nG5rEqF6SHcfx_-BazHs_4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225203754</pqid></control><display><type>article</type><title>CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Lowery, Emily G ; Spanos, Marina ; Navarro, Montserrat ; Lyons, Angela M ; Hodge, Clyde W ; Thiele, Todd E</creator><creatorcontrib>Lowery, Emily G ; Spanos, Marina ; Navarro, Montserrat ; Lyons, Angela M ; Hodge, Clyde W ; Thiele, Todd E</creatorcontrib><description>Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol consumption in C57BL/6J mice. In this report, a series of experiments were performed to further characterize the role of CRFR signaling in binge-like ethanol consumption. The role of central CRFR signaling was assessed with intracerebroventricular (i.c.v.) infusion of the nonselective CRFR antagonist, α -helical CRF 9–41 (0, 1, 5, 10 μg/1 μl). The contribution of central CRF type 2 receptor (CRF 2 R) signaling was assessed with i.c.v. infusion of the selective CRF 2 R agonist, urocortin (Ucn) 3 (0, 0.05, 0.1, or 0.5 μg/1 μl). The role of the hypothalamic–pituitary–adrenal (HPA) axis was assessed by pretreating mice with intraperitoneal (i.p.) injection of (1) the corticosterone synthesis inhibitor, metyrapone (0, 50, 100, 150 mg/kg) or (2) the glucocorticoid receptor antagonist, mifepristone (0, 25, 50 mg/kg), and (3) by using radioimmunoassay to determine whether binge-like ethanol intake influenced plasma corticosterone levels. Finally, we determined whether the ability of the CRF 1 R antagonist, CP-154,526 (CP; 0, 10, 15 mg/kg, i.p.), to blunt binge-like drinking required normal HPA axis signaling by comparing the effectiveness of CP in adrenalectomized (ADX) and normal mice. Results showed that i.c.v. infusion of a 1 μg dose of α -helical CRF 9–41 significantly attenuated binge-like ethanol consumption relative to vehicle treatment, and i.c.v. infusion of Ucn 3 dose-dependently blunted binge-like drinking. On the other hand, metyrapone nonselectively reduced both ethanol and sucrose consumption, mifepristone did not alter ethanol drinking, and binge-like drinking did not correlate with plasma corticosterone levels. Finally, i.p. injection of CP significantly attenuated binge-like ethanol intake in both ADX and normal mice. Together, these results suggest that binge-like ethanol intake in C57BL/6J mice is modulated by CRF 1 R and CRF 2 R signaling, such that blockade of CRF 1 R or activation of CRF 2 R effectively reduces excessive ethanol intake. Furthermore, normal HPA axis signaling is not necessary to achieve binge-like drinking behavior.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/npp.2009.209</identifier><identifier>PMID: 20130533</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>631/80/86 ; 631/92/436 ; 692/699/476 ; Addictive behaviors ; Adult and adolescent clinical studies ; Alcohol ; Alcohol-Induced Disorders, Nervous System - drug therapy ; Alcohol-Induced Disorders, Nervous System - metabolism ; Alcohol-Induced Disorders, Nervous System - physiopathology ; Alcoholism ; Alcoholism and acute alcohol poisoning ; Animals ; Behavior ; Behavioral Sciences ; Biological and medical sciences ; Biological Psychology ; Corticotropin-Releasing Hormone - pharmacology ; Corticotropin-Releasing Hormone - therapeutic use ; Disease Models, Animal ; Ethanol ; Hormone Antagonists - pharmacology ; Hormone Antagonists - therapeutic use ; Hypothalamo-Hypophyseal System - drug effects ; Hypothalamo-Hypophyseal System - metabolism ; Hypothalamo-Hypophyseal System - secretion ; Injections, Intraperitoneal ; Injections, Intraventricular ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Mice ; Mice, Inbred C57BL ; Mifepristone - pharmacology ; Neurosciences ; Original ; original-article ; Peptide Fragments - pharmacology ; Peptide Fragments - therapeutic use ; Peptides ; Pharmacotherapy ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Pyridines - pharmacology ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Pyrroles - pharmacology ; Pyrroles - therapeutic use ; Receptors, Corticotropin-Releasing Hormone - agonists ; Receptors, Corticotropin-Releasing Hormone - antagonists &amp; inhibitors ; Receptors, Corticotropin-Releasing Hormone - metabolism ; Signal Transduction - drug effects ; Signal Transduction - physiology ; Toxicology ; Urocortins - pharmacology ; Urocortins - therapeutic use</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2010-05, Vol.35 (6), p.1241-1252</ispartof><rights>American College of Neuropsychopharmacology 2010</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group May 2010</rights><rights>Copyright © 2010 American College of Neuropsychopharmacology 2010 American College of Neuropsychopharmacology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-9f3dc23d61390e81f07f51be69853dcee8104e9974a0627f0c8cf36b9ef6e4263</citedby><cites>FETCH-LOGICAL-c576t-9f3dc23d61390e81f07f51be69853dcee8104e9974a0627f0c8cf36b9ef6e4263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927867/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927867/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22769569$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20130533$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lowery, Emily G</creatorcontrib><creatorcontrib>Spanos, Marina</creatorcontrib><creatorcontrib>Navarro, Montserrat</creatorcontrib><creatorcontrib>Lyons, Angela M</creatorcontrib><creatorcontrib>Hodge, Clyde W</creatorcontrib><creatorcontrib>Thiele, Todd E</creatorcontrib><title>CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacol</addtitle><addtitle>Neuropsychopharmacology</addtitle><description>Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol consumption in C57BL/6J mice. In this report, a series of experiments were performed to further characterize the role of CRFR signaling in binge-like ethanol consumption. The role of central CRFR signaling was assessed with intracerebroventricular (i.c.v.) infusion of the nonselective CRFR antagonist, α -helical CRF 9–41 (0, 1, 5, 10 μg/1 μl). The contribution of central CRF type 2 receptor (CRF 2 R) signaling was assessed with i.c.v. infusion of the selective CRF 2 R agonist, urocortin (Ucn) 3 (0, 0.05, 0.1, or 0.5 μg/1 μl). The role of the hypothalamic–pituitary–adrenal (HPA) axis was assessed by pretreating mice with intraperitoneal (i.p.) injection of (1) the corticosterone synthesis inhibitor, metyrapone (0, 50, 100, 150 mg/kg) or (2) the glucocorticoid receptor antagonist, mifepristone (0, 25, 50 mg/kg), and (3) by using radioimmunoassay to determine whether binge-like ethanol intake influenced plasma corticosterone levels. Finally, we determined whether the ability of the CRF 1 R antagonist, CP-154,526 (CP; 0, 10, 15 mg/kg, i.p.), to blunt binge-like drinking required normal HPA axis signaling by comparing the effectiveness of CP in adrenalectomized (ADX) and normal mice. Results showed that i.c.v. infusion of a 1 μg dose of α -helical CRF 9–41 significantly attenuated binge-like ethanol consumption relative to vehicle treatment, and i.c.v. infusion of Ucn 3 dose-dependently blunted binge-like drinking. On the other hand, metyrapone nonselectively reduced both ethanol and sucrose consumption, mifepristone did not alter ethanol drinking, and binge-like drinking did not correlate with plasma corticosterone levels. Finally, i.p. injection of CP significantly attenuated binge-like ethanol intake in both ADX and normal mice. Together, these results suggest that binge-like ethanol intake in C57BL/6J mice is modulated by CRF 1 R and CRF 2 R signaling, such that blockade of CRF 1 R or activation of CRF 2 R effectively reduces excessive ethanol intake. Furthermore, normal HPA axis signaling is not necessary to achieve binge-like drinking behavior.</description><subject>631/80/86</subject><subject>631/92/436</subject><subject>692/699/476</subject><subject>Addictive behaviors</subject><subject>Adult and adolescent clinical studies</subject><subject>Alcohol</subject><subject>Alcohol-Induced Disorders, Nervous System - drug therapy</subject><subject>Alcohol-Induced Disorders, Nervous System - metabolism</subject><subject>Alcohol-Induced Disorders, Nervous System - physiopathology</subject><subject>Alcoholism</subject><subject>Alcoholism and acute alcohol poisoning</subject><subject>Animals</subject><subject>Behavior</subject><subject>Behavioral Sciences</subject><subject>Biological and medical sciences</subject><subject>Biological Psychology</subject><subject>Corticotropin-Releasing Hormone - pharmacology</subject><subject>Corticotropin-Releasing Hormone - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Ethanol</subject><subject>Hormone Antagonists - pharmacology</subject><subject>Hormone Antagonists - therapeutic use</subject><subject>Hypothalamo-Hypophyseal System - drug effects</subject><subject>Hypothalamo-Hypophyseal System - metabolism</subject><subject>Hypothalamo-Hypophyseal System - secretion</subject><subject>Injections, Intraperitoneal</subject><subject>Injections, Intraventricular</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mifepristone - pharmacology</subject><subject>Neurosciences</subject><subject>Original</subject><subject>original-article</subject><subject>Peptide Fragments - pharmacology</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Peptides</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Pyridines - pharmacology</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Pyrroles - pharmacology</subject><subject>Pyrroles - therapeutic use</subject><subject>Receptors, Corticotropin-Releasing Hormone - agonists</subject><subject>Receptors, Corticotropin-Releasing Hormone - antagonists &amp; inhibitors</subject><subject>Receptors, Corticotropin-Releasing Hormone - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - physiology</subject><subject>Toxicology</subject><subject>Urocortins - pharmacology</subject><subject>Urocortins - therapeutic use</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkd1rFDEUxYModlt981mCIL44bT5mksmLMN22trKiiELfQjZ7s5t2NhmT2aL_vVl2bVV8uYFzfzk54SD0gpJjSnh7EobhmBGiylCP0ITKmlSC19eP0YS0ileU8-sDdJjzDSG0kaJ9ig4YoZw0nE_QOP1yUVHchdEsY_B5xCYs8FZkuNsrZ2ATmAz41IclVDN_C_h8XJkQe3yWfLgtMvYBTxt5OjsRH_BHbwFfhQUMUEYYcXR4XAG-_Nzh7ofPz9ATZ_oMz_fnEfp2cf51elnNPr2_mnazypacY6UcX1jGF4JyRaCljkjX0DkI1TZlA0UiNSgla0MEk47Y1jou5gqcgJoJfoTe7XyHzXwN5UYYk-n1kPzapJ86Gq__3gS_0st4p5lishWyGLzZG6T4fQN51GufLfS9CRA3WctaEEob0hby1T_kTdykUH6nGWsY4bKpC_R2B9kUc07g7qNQordl6lKm3pZZhir4yz_j38O_2yvA6z1gsjW9SyZYnx84JoVqxNao2nG5rEqF6SHcfx_-BazHs_4</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Lowery, Emily G</creator><creator>Spanos, Marina</creator><creator>Navarro, Montserrat</creator><creator>Lyons, Angela M</creator><creator>Hodge, Clyde W</creator><creator>Thiele, Todd E</creator><general>Springer International Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20100501</creationdate><title>CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis</title><author>Lowery, Emily G ; Spanos, Marina ; Navarro, Montserrat ; Lyons, Angela M ; Hodge, Clyde W ; Thiele, Todd E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-9f3dc23d61390e81f07f51be69853dcee8104e9974a0627f0c8cf36b9ef6e4263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>631/80/86</topic><topic>631/92/436</topic><topic>692/699/476</topic><topic>Addictive behaviors</topic><topic>Adult and adolescent clinical studies</topic><topic>Alcohol</topic><topic>Alcohol-Induced Disorders, Nervous System - drug therapy</topic><topic>Alcohol-Induced Disorders, Nervous System - metabolism</topic><topic>Alcohol-Induced Disorders, Nervous System - physiopathology</topic><topic>Alcoholism</topic><topic>Alcoholism and acute alcohol poisoning</topic><topic>Animals</topic><topic>Behavior</topic><topic>Behavioral Sciences</topic><topic>Biological and medical sciences</topic><topic>Biological Psychology</topic><topic>Corticotropin-Releasing Hormone - pharmacology</topic><topic>Corticotropin-Releasing Hormone - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Ethanol</topic><topic>Hormone Antagonists - pharmacology</topic><topic>Hormone Antagonists - therapeutic use</topic><topic>Hypothalamo-Hypophyseal System - drug effects</topic><topic>Hypothalamo-Hypophyseal System - metabolism</topic><topic>Hypothalamo-Hypophyseal System - secretion</topic><topic>Injections, Intraperitoneal</topic><topic>Injections, Intraventricular</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mifepristone - pharmacology</topic><topic>Neurosciences</topic><topic>Original</topic><topic>original-article</topic><topic>Peptide Fragments - pharmacology</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Peptides</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Pyridines - pharmacology</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Pyrroles - pharmacology</topic><topic>Pyrroles - therapeutic use</topic><topic>Receptors, Corticotropin-Releasing Hormone - agonists</topic><topic>Receptors, Corticotropin-Releasing Hormone - antagonists &amp; inhibitors</topic><topic>Receptors, Corticotropin-Releasing Hormone - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - physiology</topic><topic>Toxicology</topic><topic>Urocortins - pharmacology</topic><topic>Urocortins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lowery, Emily G</creatorcontrib><creatorcontrib>Spanos, Marina</creatorcontrib><creatorcontrib>Navarro, Montserrat</creatorcontrib><creatorcontrib>Lyons, Angela M</creatorcontrib><creatorcontrib>Hodge, Clyde W</creatorcontrib><creatorcontrib>Thiele, Todd E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lowery, Emily G</au><au>Spanos, Marina</au><au>Navarro, Montserrat</au><au>Lyons, Angela M</au><au>Hodge, Clyde W</au><au>Thiele, Todd E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><stitle>Neuropsychopharmacol</stitle><addtitle>Neuropsychopharmacology</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>35</volume><issue>6</issue><spage>1241</spage><epage>1252</epage><pages>1241-1252</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>Recent evidence suggests that corticotropin-releasing factor (CRF) receptor (CRFR) signaling is involved in modulating binge-like ethanol consumption in C57BL/6J mice. In this report, a series of experiments were performed to further characterize the role of CRFR signaling in binge-like ethanol consumption. The role of central CRFR signaling was assessed with intracerebroventricular (i.c.v.) infusion of the nonselective CRFR antagonist, α -helical CRF 9–41 (0, 1, 5, 10 μg/1 μl). The contribution of central CRF type 2 receptor (CRF 2 R) signaling was assessed with i.c.v. infusion of the selective CRF 2 R agonist, urocortin (Ucn) 3 (0, 0.05, 0.1, or 0.5 μg/1 μl). The role of the hypothalamic–pituitary–adrenal (HPA) axis was assessed by pretreating mice with intraperitoneal (i.p.) injection of (1) the corticosterone synthesis inhibitor, metyrapone (0, 50, 100, 150 mg/kg) or (2) the glucocorticoid receptor antagonist, mifepristone (0, 25, 50 mg/kg), and (3) by using radioimmunoassay to determine whether binge-like ethanol intake influenced plasma corticosterone levels. Finally, we determined whether the ability of the CRF 1 R antagonist, CP-154,526 (CP; 0, 10, 15 mg/kg, i.p.), to blunt binge-like drinking required normal HPA axis signaling by comparing the effectiveness of CP in adrenalectomized (ADX) and normal mice. Results showed that i.c.v. infusion of a 1 μg dose of α -helical CRF 9–41 significantly attenuated binge-like ethanol consumption relative to vehicle treatment, and i.c.v. infusion of Ucn 3 dose-dependently blunted binge-like drinking. On the other hand, metyrapone nonselectively reduced both ethanol and sucrose consumption, mifepristone did not alter ethanol drinking, and binge-like drinking did not correlate with plasma corticosterone levels. Finally, i.p. injection of CP significantly attenuated binge-like ethanol intake in both ADX and normal mice. Together, these results suggest that binge-like ethanol intake in C57BL/6J mice is modulated by CRF 1 R and CRF 2 R signaling, such that blockade of CRF 1 R or activation of CRF 2 R effectively reduces excessive ethanol intake. Furthermore, normal HPA axis signaling is not necessary to achieve binge-like drinking behavior.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>20130533</pmid><doi>10.1038/npp.2009.209</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0893-133X
ispartof Neuropsychopharmacology (New York, N.Y.), 2010-05, Vol.35 (6), p.1241-1252
issn 0893-133X
1740-634X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2927867
source MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects 631/80/86
631/92/436
692/699/476
Addictive behaviors
Adult and adolescent clinical studies
Alcohol
Alcohol-Induced Disorders, Nervous System - drug therapy
Alcohol-Induced Disorders, Nervous System - metabolism
Alcohol-Induced Disorders, Nervous System - physiopathology
Alcoholism
Alcoholism and acute alcohol poisoning
Animals
Behavior
Behavioral Sciences
Biological and medical sciences
Biological Psychology
Corticotropin-Releasing Hormone - pharmacology
Corticotropin-Releasing Hormone - therapeutic use
Disease Models, Animal
Ethanol
Hormone Antagonists - pharmacology
Hormone Antagonists - therapeutic use
Hypothalamo-Hypophyseal System - drug effects
Hypothalamo-Hypophyseal System - metabolism
Hypothalamo-Hypophyseal System - secretion
Injections, Intraperitoneal
Injections, Intraventricular
Male
Medical sciences
Medicine
Medicine & Public Health
Mice
Mice, Inbred C57BL
Mifepristone - pharmacology
Neurosciences
Original
original-article
Peptide Fragments - pharmacology
Peptide Fragments - therapeutic use
Peptides
Pharmacotherapy
Psychiatry
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Pyridines - pharmacology
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Pyrroles - pharmacology
Pyrroles - therapeutic use
Receptors, Corticotropin-Releasing Hormone - agonists
Receptors, Corticotropin-Releasing Hormone - antagonists & inhibitors
Receptors, Corticotropin-Releasing Hormone - metabolism
Signal Transduction - drug effects
Signal Transduction - physiology
Toxicology
Urocortins - pharmacology
Urocortins - therapeutic use
title CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA Axis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A47%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CRF-1%20Antagonist%20and%20CRF-2%20Agonist%20Decrease%20Binge-Like%20Ethanol%20Drinking%20in%20C57BL/6J%20Mice%20Independent%20of%20the%20HPA%20Axis&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Lowery,%20Emily%20G&rft.date=2010-05-01&rft.volume=35&rft.issue=6&rft.spage=1241&rft.epage=1252&rft.pages=1241-1252&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/npp.2009.209&rft_dat=%3Cproquest_pubme%3E746011508%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225203754&rft_id=info:pmid/20130533&rfr_iscdi=true